JP2007515431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515431A5 JP2007515431A5 JP2006545655A JP2006545655A JP2007515431A5 JP 2007515431 A5 JP2007515431 A5 JP 2007515431A5 JP 2006545655 A JP2006545655 A JP 2006545655A JP 2006545655 A JP2006545655 A JP 2006545655A JP 2007515431 A5 JP2007515431 A5 JP 2007515431A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- disease
- group
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010061218 Inflammation Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 4
- 208000014311 Cushing syndrome Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 4
- 208000004880 Polyuria Diseases 0.000 claims 4
- 206010042957 Systolic hypertension Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000016998 Conn syndrome Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010012758 Diastolic hypertension Diseases 0.000 claims 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 2
- 206010059284 Epidermal necrosis Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010015226 Erythema nodosum Diseases 0.000 claims 2
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020112 Hirsutism Diseases 0.000 claims 2
- 206010020564 Hyperadrenocorticism Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010024229 Leprosy Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000010428 Muscle Weakness Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims 2
- 206010039808 Secondary aldosteronism Diseases 0.000 claims 2
- 206010041277 Sodium retention Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010056091 Varices oesophageal Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 208000006752 brain edema Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 208000001969 capillary hemangioma Diseases 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 150000003943 catecholamines Chemical class 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000009508 confectionery Nutrition 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024170 esophageal varices Diseases 0.000 claims 2
- 201000010120 esophageal varix Diseases 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 208000004526 exfoliative dermatitis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010033675 panniculitis Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 208000013846 primary aldosteronism Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 210000004761 scalp Anatomy 0.000 claims 2
- 208000023087 secondary adrenal insufficiency Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000016261 weight loss Diseases 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000001780 adrenocortical effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 206010036067 polydipsia Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CC(C)(C)CC1N(*)CCC1 Chemical compound CC(C)(C)CC1N(*)CCC1 0.000 description 7
- HLNRRPIYRBBHSQ-UHFFFAOYSA-N CCCN1CCCC1 Chemical compound CCCN1CCCC1 HLNRRPIYRBBHSQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53128303P | 2003-12-19 | 2003-12-19 | |
| US60/531,283 | 2003-12-19 | ||
| PCT/US2004/038233 WO2005066161A1 (en) | 2003-12-19 | 2004-12-08 | Tricyclic steroid hormone nuclear receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007515431A JP2007515431A (ja) | 2007-06-14 |
| JP2007515431A5 true JP2007515431A5 (cg-RX-API-DMAC7.html) | 2008-01-24 |
| JP4846596B2 JP4846596B2 (ja) | 2011-12-28 |
Family
ID=34748755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545655A Expired - Fee Related JP4846596B2 (ja) | 2003-12-19 | 2004-12-08 | 三環系のステロイドホルモン核内受容体モジュレータ |
Country Status (21)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| EP1838672B1 (en) * | 2004-12-23 | 2015-02-18 | Athersys, Inc. | 4-piperidinol tertiary amines as histamine 3 receptor inhibitors for the treatment of obesity and other cns disorders |
| DE102005022020A1 (de) * | 2005-05-12 | 2006-11-23 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| US8034940B2 (en) | 2006-08-09 | 2011-10-11 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| ES2375877T3 (es) | 2006-10-31 | 2012-03-07 | Pfizer Products Inc. | Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides. |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| ES2370148T3 (es) * | 2008-01-11 | 2011-12-13 | Eli Lilly & Company | (e)-n-{3-[fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-ciclohepten-5-iliden)-propil]-fenil}-metilsulfonamida como modulador del receptor de glucocorticoides para el tratamiento de artritis reumatoide. |
| JPWO2010001990A1 (ja) * | 2008-07-03 | 2011-12-22 | 協和発酵キリン株式会社 | 四環系化合物 |
| WO2010104721A1 (en) | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| EP2638012A1 (en) | 2010-11-10 | 2013-09-18 | Boehringer Ingelheim International GmbH | Pyridyl ureas as mineralocorticoid receptor antagonists |
| KR20140051998A (ko) * | 2011-08-03 | 2014-05-02 | 교와 핫꼬 기린 가부시키가이샤 | 디벤조옥세핀 유도체 |
| CN116783181B (zh) * | 2021-04-12 | 2026-01-30 | 上海瑛派药业有限公司 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2603713B1 (fr) * | 1986-09-10 | 1992-07-24 | Canon Kk | Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant |
| JPH01161245A (ja) | 1987-12-18 | 1989-06-23 | Canon Inc | 電子写真感光体 |
| US4999363A (en) * | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5093210A (en) * | 1989-06-30 | 1992-03-03 | Ricoh Company, Ltd. | Electroluminescent device |
| JPH0446352A (ja) | 1990-06-14 | 1992-02-17 | Minolta Camera Co Ltd | 感光体 |
| US6372779B1 (en) * | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| EP1154997A4 (en) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE |
| US7087636B2 (en) * | 2001-12-19 | 2006-08-08 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
| JP2006508893A (ja) | 2002-03-15 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−2−オン誘導体 |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
-
2004
- 2004-12-08 DE DE602004014640T patent/DE602004014640D1/de not_active Expired - Lifetime
- 2004-12-08 PT PT04811084T patent/PT1697350E/pt unknown
- 2004-12-08 SI SI200430840T patent/SI1697350T1/sl unknown
- 2004-12-08 WO PCT/US2004/038233 patent/WO2005066161A1/en not_active Ceased
- 2004-12-08 CN CNA2004800418534A patent/CN1918151A/zh active Pending
- 2004-12-08 ES ES04811084T patent/ES2308296T3/es not_active Expired - Lifetime
- 2004-12-08 DK DK04811084T patent/DK1697350T3/da active
- 2004-12-08 CA CA2549053A patent/CA2549053C/en not_active Expired - Fee Related
- 2004-12-08 AU AU2004312293A patent/AU2004312293A1/en not_active Abandoned
- 2004-12-08 JP JP2006545655A patent/JP4846596B2/ja not_active Expired - Fee Related
- 2004-12-08 MX MXPA06007055A patent/MXPA06007055A/es unknown
- 2004-12-08 EP EP04811084A patent/EP1697350B1/en not_active Expired - Lifetime
- 2004-12-08 PL PL04811084T patent/PL1697350T3/pl unknown
- 2004-12-08 BR BRPI0416882-8A patent/BRPI0416882A/pt not_active Application Discontinuation
- 2004-12-08 US US10/576,761 patent/US7803814B2/en not_active Expired - Fee Related
- 2004-12-08 AT AT04811084T patent/ATE399163T1/de not_active IP Right Cessation
- 2004-12-17 AR ARP040104730A patent/AR046951A1/es unknown
-
2006
- 2006-05-29 IL IL175996A patent/IL175996A0/en unknown
- 2006-06-13 ZA ZA200604889A patent/ZA200604889B/en unknown
- 2006-07-18 NO NO20063329A patent/NO20063329L/no not_active Application Discontinuation
-
2008
- 2008-09-03 CY CY20081100936T patent/CY1108309T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2489276A1 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| CA2549053A1 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| ES2559687T3 (es) | Composición y métodos para modular una cascada de cinasa | |
| WO2024217557A1 (zh) | 取代的四氢呋喃作为Nav1.8抑制剂 | |
| TWI445705B (zh) | 經苯基及苯并二基取代之吲唑衍生物 | |
| JP6001771B2 (ja) | mPGES−1阻害剤としてのトリアゾロン化合物 | |
| JP2007515413A5 (cg-RX-API-DMAC7.html) | ||
| Montagu et al. | Synthesis of new C5-(1-substituted-1, 2, 3-triazol-4 or 5-yl)-2′-deoxyuridines and their antiviral evaluation | |
| CA2519677A1 (en) | Biaryl substituted 6-membered heterocycles as sodium channel blockers | |
| TW200306838A (en) | Chemical compounds | |
| TW200927733A (en) | Novel compounds and compositions and methods of use | |
| JP2013545812A5 (cg-RX-API-DMAC7.html) | ||
| CA2755348A1 (en) | Substituted aryl antiviral compounds and uses thereof | |
| TW200306834A (en) | Aminopyrimidine compound and pharmaceutical use thereof | |
| CN1043231C (zh) | (E)-α-去氧-α-(氟亚甲基)胞苷的一水合物 | |
| ES2929799T3 (es) | Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4 | |
| CN102250189A (zh) | 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途 | |
| AU6491398A (en) | Pyridazinones as inhibitors of cyclooxygenase-2 | |
| WO2018021520A1 (ja) | グアニジン誘導体及びその医薬用途 | |
| CN111892636A (zh) | 一种阿兹夫定的合成方法 | |
| JP2025148397A5 (cg-RX-API-DMAC7.html) | ||
| Tang et al. | Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses | |
| JP2010534670A5 (cg-RX-API-DMAC7.html) | ||
| CN110885318B (zh) | 苯并恶唑衍生物及其制备方法和应用 | |
| TW200815362A (en) | Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors |